The pharma giant reported that the drug did not produce a statistically significant improvement in the risk of heart attack, stroke or death, though it added that "greater reductions" for some of the secondary endpoints warranted careful follow-up review as investigators considered its potential.
GlaxoSmithKline has racked up a slate of drug approvals this year, an impressive accomplishment for a company that had to endure a lengthy fallow period in R&D after it reorganized its extensive research operations.
Does the Justice Department's off-label marketing enforcement actually deter bad behavior? That's been up for debate as one drugmaker after another agreed to pay hundreds of millions of...
Whether the Justice Department's off-label marketing enforcement actually deters bad behavior has been up for debate as one drugmaker after another agreed to pay hundreds of millions of dollars to settle federal investigations--some of them repeat offenders.
In Big Pharma, you're only as good as your pipeline, your product lineup and how you shape up relative to the threat of a looming loss of patent protection. And by that criteria Morningstar's top pharma analyst ranks GlaxoSmithKline at the top of the industry heap, with AstraZeneca limping in at last place despite a flurry of new deals aimed at reviving its R&D efforts.
GlaxoSmithKline has rounded up some early preclinical projects in its inaugural Discovery Fast Track competition, hand-picking academic scientists for a chance to partner up and kick-start their research into a development program.
While half of U.S. teenage girls receive one dose of human papillomavirus vaccine, far fewer come back to complete the regimen. What is less clear is whether one dose offers any protection, but a new study offers some hope.
GlaxoSmithKline bigwigs can breathe a sigh of relief, if a tentative one. The company probably won't face corruption charges in China, Reuters sources say. But Glaxo's local executives probably will.
GlaxoSmithKline's Advair is hard to copy. Some companies have given up on generic Advair, while others have shied away altogether despite the substantial sales up for grabs. But what if generics makers had some help--and an expedited review process--from the FDA?
GlaxoSmithKline has again said it will close a consumer healthcare plant in Clifton, NJ, and move production to a facility in New York.